New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:12 EDTRCPTReceptos says Phase 2 study of RPC1063 met primary efficacy endpoint
Receptos announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTRCPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:55 EDTRCPTReceptos initiated with a Buy at UBS
Subscribe for More Information
April 16, 2015
09:30 EDTRCPTReceptos announcement a positive surprise, says Leerink
Subscribe for More Information
08:08 EDTRCPTReceptos reports positive results for maintenance period of ozanimod trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use